Related Experiment Video
Updated: Jul 4, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
[New molecular targets in pancreatic cancer]
Jérôme Torrisani1, Barbara Bournet, Pierre Cordelier
1Inserm U858, Institut de médecine moléculaire et Service de gastro-entérologie et nutrition, CHU Rangueil, TSA 50032, 31059 Toulouse Cedex 9.
Abstract:
The understanding of the biology of pancreatic carcinoma has greatly benefited from studies of genetic alterations and molecular expression in experimental models as well as in pre-cancerous and cancerous tissues by mean of molecular amplification and large scale transcriptome analysis. P16, TP53, DPC4/Smad4 tumor suppressor pathways are genetically inactivated in the majority of pancreatic carcinomas, whereas oncogenic k-ras is activated. The activating mutation of the K-ras oncogene on codon 12 seems to occur early in pancreatic carcinogenesis and detecting its mutation in tumor samples could have a clinical relevance in term of positive (improvement of current histological diagnosis) and differential diagnosis (versus chronic pancreatitis) of pancreatic cancer. At a late stage of tumor development, an increase of telomerase activity, an over expression of growth factors and/or their receptors (EGF, nerve growth factor, gastrin, bombesin), of proangiogenic factors (VEGF, FGF, PDGF), of invasiveness factors (metalloproteinases, E-cadherin, beta integrin, urokinase and tissue plasminogen activator) occur. All these molecular events contribute to the progression and to the metastatic potential of this carcinoma. New markers and targets are currently studied among microRNA and epigenetics events such as methylation and acetylation. Among all these molecular markers, some are now tested for their potential clinical interest in term of diagnosis or therapeutic target.
Insights
Pancreatic cancer research identifies key genetic changes, including tumor suppressor inactivation and K-ras activation, crucial for early detection and diagnosis. Understanding these molecular events aids in developing new diagnostic markers and therapeutic targets for pancreatic carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Pancreatic carcinoma biology is increasingly understood through genetic alterations and molecular expression.
- Studies utilize experimental models and analyze pre-cancerous and cancerous tissues via molecular amplification and transcriptome analysis.
Purpose:
- To review the genetic alterations and molecular expression patterns in pancreatic carcinoma.
- To highlight the clinical relevance of detecting specific mutations, such as K-ras, for diagnosis and differential diagnosis.
- To identify molecular events contributing to tumor progression and metastatic potential.
Summary:
- Key genetic alterations in pancreatic cancer include inactivation of P16, TP53, and DPC4/Smad4 tumor suppressor pathways, alongside activation of the oncogenic K-ras gene.
- Activating mutations in K-ras codon 12 occur early in carcinogenesis, offering potential for improved histological and differential diagnosis of pancreatic cancer.
- Later stages involve increased telomerase activity and overexpression of growth factors, proangiogenic factors, and invasiveness factors, driving tumor progression and metastasis.
Impact:
- Identifies critical molecular markers for potential clinical application in pancreatic cancer diagnosis.
- Highlights K-ras mutation detection as valuable for improving diagnostic accuracy and differentiating cancer from chronic pancreatitis.
- Suggests ongoing research into microRNAs and epigenetic events (methylation, acetylation) for novel therapeutic targets and diagnostic markers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...